Patent · US Active

Materials and methods of treating MHC-I-opathy risk haplotypes

US12370257B2 · kind B2 · utility

0Cited by

8References

13Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Sahar Gelfman · Tarrytown, US
Ann Ligocki · Tarrytown, US
Giovanni Coppola · Tarrytown, US
Aris Baras · Tarrytown, US
Arden Moscati · Tarrytown, US
Eli A. Stahl · Tarrytown, US
Jack A. Kosmicki · Tarrytown, US
Manuel Allen Revez Ferreira · Cocoa, US
Carmelo Romano · Tarrytown, US

Key dates

Filing date	Apr 6, 2022
Grant date	Jul 29, 2025
Priority date	—
Expiry date	Apr 14, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q1/6881
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.